Is Kava a Drug?

In 2002, German regulators pulled kava off the shelves following a cluster of liver injury reports. Thirteen years later, in 2015, a German court overturned the ban, finding that the original evidence had been misread and the regulatory response disproportionate. Kava products returned to the German market — and the story of that reversal is, in many ways, the story of how Europe is still working out what kava actually is.

Is it a drug? A supplement? A food? A traditional beverage? The honest answer is that kava (Piper methysticum) sits in a category of its own. It's psychoactive, but it isn't addictive. It's regulated, but it isn't scheduled. It's been consumed safely in the Pacific for at least three thousand years, yet European regulators still can't agree on what shelf it belongs on. To understand why, you have to look at the question from three angles: the law, the pharmacology, and the comparison to substances we already have a clear opinion on.

The Legal Picture Across Europe

The German story is the most consequential, but it isn't the only one. After the 2002 hepatotoxicity reports, several European countries restricted kava in various ways, and the World Health Organization launched a full safety review. When that review concluded the evidence didn't justify a blanket ban, the legal landscape began to shift back.

Today, kava's status in Europe is a patchwork. Germany permits it. In the UK, sale of kava as a medicinal product remains restricted under the 2002 prohibition order, but possession and consumption are not criminalised — and traditional or food-grade preparations occupy a grey area that has been increasingly tested by retailers. Several other EU member states treat kava as a botanical food or ethnobotanical product, subject to general food safety law rather than narcotics control. The EU's Novel Food framework continues to influence how new kava products can be marketed, particularly for extracts and concentrates as opposed to the traditional water-prepared beverage.

Crucially, nowhere in Europe is kava classified alongside controlled narcotics, opioids, or scheduled depressants. The dispute, where it exists, is about how it should be regulated as a consumer product — not about whether it belongs in the same category as cocaine or heroin.

The Pharmacological Answer Is More Interesting

Kava's active compounds are called kavalactones — a group of about eighteen lipophilic molecules, with kavain, methysticin, and yangonin doing most of the heavy lifting. They produce relaxation, mild euphoria, sociability, and a characteristic numbing of the lips and tongue.

Mechanistically, kavalactones are positive allosteric modulators of GABA-A receptors. That sounds technical, but the practical meaning is straightforward: they make the brain's primary "calm down" signal work more efficiently. A 2016 study published in PLOS One by researchers at the University of Sydney confirmed that kavain directly potentiates GABA-A receptors — but crucially, not at the benzodiazepine binding site. That distinction matters, because it's part of why kava behaves so differently from drugs that target the same system.

Kavalactones also inhibit voltage-gated calcium channels and appear to reversibly inhibit monoamine oxidase-B, which may explain the mild mood lift many users describe.

Kava vs Alcohol: Same Target, Very Different Outcome

Alcohol also acts on GABA receptors, which is why people often describe kava as alcohol-adjacent. But alcohol is a blunt instrument — it also hits glutamate receptors, sodium channels, and dozens of other systems, which is what produces the slurring, the impaired coordination, and the memory loss.

Kava doesn't do this. Studies have repeatedly shown that low to moderate doses preserve cognitive performance and reaction time. Captain Cook's crew first compared kava to alcohol when they encountered it in the 18th century, but when missionaries later introduced alcohol to kava-drinking societies, the cultural and health consequences were immediate and severe. Kava drinkers tend toward conversation; alcohol drinkers, statistically, do not.

Kava vs Benzodiazepines: Comparable Effect, Different Footprint

Multiple randomised controlled trials have found kava's anxiolytic effects comparable to low-dose benzodiazepines like diazepam, as well as to buspirone and opipramol — but with fewer sedative side effects. The critical difference is dependency. Benzodiazepines are notoriously habit-forming, with well-documented withdrawal syndromes. Kava has no equivalent profile.

In fact, kava exhibits what researchers call "reverse tolerance": new users often need larger amounts to feel the effects than experienced drinkers do — the opposite of how addictive drugs behave.

Dr. Vincent Lebot, one of the world's leading kava researchers, has stated plainly that kava is not classified as a drug by pharmacological standards, because long-term users do not develop dependency or experience withdrawal when they stop.

Kava vs Kratom: Often Compared, Genuinely Different

Kava is frequently shelved next to kratom in herbal shops, but pharmacologically they're not in the same family. Kratom's active alkaloids bind to opioid receptors, which is why it can be useful for pain relief — and why it carries genuine dependence risk, withdrawal symptoms, and a legal status that varies wildly across European countries. Kava works through GABA, doesn't engage the opioid system at all, and has no equivalent dependency profile.

What the WHO Concluded

The most thorough review of kava safety was the World Health Organization's 2007 Assessment of the Risk of Hepatotoxicity with Kava Products, followed by a 2016 FAO/WHO technical report on traditional consumption. The 2007 committee concluded that the condemnation of kava extracts appears unwarrantable, finding a hepatotoxicity incidence of roughly 0.02 cases per one million daily doses — orders of magnitude below the liver risk associated with common pharmaceuticals, including the very benzodiazepines kava is sometimes proposed as an alternative to.

The 2016 review went further, finding that even heavy traditional kava drinkers showed no link to liver disease, with the only reliable adverse effects being a reversible scaly skin condition (kava dermopathy) and temporarily elevated liver enzymes that returned to normal once consumption stopped. It was this body of evidence that underpinned the German court's 2015 decision to overturn the original ban.

Dr. 'Apo' Aporosa at the University of Waikato — probably the most cited contemporary kava researcher — has argued for years that the early 2000s panic was driven by poor-quality extracts using stems and leaves rather than the traditional root, and that traditionally prepared kava has a safety record most pharmaceuticals would envy.

So, Is Kava a Drug?

The most accurate answer is that kava is a psychoactive plant beverage that produces measurable effects on the central nervous system without meeting the standard criteria used to define a drug of abuse: it does not produce dependency, does not develop tolerance, does not cause withdrawal, and is not classified as a controlled substance anywhere in Europe.

Culturally it sits closer to coffee or wine than to anything in a pharmacy bottle. Pharmacologically, it's its own category — and that's exactly why the question keeps coming up.